We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.90 | 2.80 | 3.00 | 2.95 | 2.90 | 2.90 | 782,547 | 08:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.22 | 138.23M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/4/2014 20:13 | RNS says they hold 25%...... Total (A+B+C) Number of voting rights Percentage of voting rights -------------------- 103,457,784 25.24% | audigger | |
02/4/2014 20:09 | Rule 9 of the takeover code states any investor holding 29.9% or above is obliged to make an offer for the company. | barefoot141 | |
02/4/2014 19:53 | Think it's 33.7% but not sure it triggers a bid? | cube boss | |
02/4/2014 19:10 | Hi Jimmy, Southern Fox / Chase Nom is an Investment company When it says Crossed or Reached, it means have they added or sold! in this case they have added around 1.25 mill, They added around 3/4 weeks ago if you look back, a similar RNS came out then! They have been adding for the last few years. Every time a company adds or sells, if they hold over 3%, then the mentioned Company have to publish an RNS. If a company holds, I think it's 33% then they can make a bid for the company, but I think they are adding for their investors as they see value in AGY. Will check on the % and get back soon..:0) | cube boss | |
02/4/2014 18:10 | Cube et al, can you explain for me and the masses what this RNS means please What stake triggers a bid? | jimmyloser | |
02/4/2014 15:26 | A little positive news from yesterday: Allergy Therapeutics plc (LON:AGY) had its target price boosted by Panmure Gordon from GBX 16 ($0.27) to GBX 25 ($0.42). The firm currently has a buy rating on the stock. FG | farmer george | |
02/4/2014 11:45 | Well, it's the long game we are in for and any positive news flow will move the share price up sharply IMHO. FG | farmer george | |
02/4/2014 11:26 | Looks like the seller is out, think someone is taking all sells! Max buy is 37k online..:0) | cube boss | |
02/4/2014 09:29 | Not looking good Barefoot, nothing has changed guys! amazing how a few small trades takes us down 7/8%. Time for a dog walk me thinks...:0) | cube boss | |
01/4/2014 18:45 | Ah the ole 62% fib retrace bounce. I bloody hope so as another not to be mentioned on this thread biotech company is near this point as well. If wrong i'm surrender...... | barefoot141 | |
01/4/2014 18:38 | Be afraid, very afraid if you have jumped ship here....impo The CEO didn't make the statement about "compelling reasons to be first to market" for filling a page! dyor......today was very significant. | jimmyloser | |
01/4/2014 18:14 | Now for the next leg, traders will pour in tomorrow IMO and back up to test the 30 again. Nice 50% for traders in the short term, but much greater for the lti's | big7ime | |
01/4/2014 12:00 | Nice bit of Blue at last guys..:0)) | cube boss | |
01/4/2014 11:45 | My word we have a tint of blue! Here's an interesting thought. What if "management" were sat on a major RNS that menat they had significant insider knowledge. Would that preclude them from buying? | audigger | |
01/4/2014 08:22 | This really needs T H to put his money were the companies mouth is, i find it a tad worrying that he still has not bought IF the prospects look so good I still hold but only just i need to see a commitment to keep SOON | mykai | |
31/3/2014 15:26 | The chart is starting to look a bit ill. I think 18.4 is key. If we fall through that then I'm out! Here's hoping we bounce! | audigger | |
31/3/2014 13:05 | hello barefoot slight of topic good set of results at inl dissapointing reaction though | sigora | |
31/3/2014 13:02 | Saturn. I'm afraid it was that straight forward we would all be rich. From a technical perspective it depends where the share price finds support as shares tend do go up in stages and not a straight line. Next leg up or not will be quite important. However that aside the company, partnerships and products look good for the future. i tend to use the charts for entry and exist points and to establish where support/resistance is (market sentiment). | barefoot141 | |
31/3/2014 12:50 | I bought some of these shares on the basis of that great rise in the share price on the chart,but then it collapsed. Just goes to show you cannot trust charts or their indicators. | saturn5 | |
31/3/2014 09:16 | Morning guys, very quiet here today, think it's settled for a while.:0) | cube boss | |
30/3/2014 13:08 | "The combination of Endo and Paladin Labs accelerates Endo's transformation into a leading global specialty healthcare company and establishes a platform for additional strategic acquisitions," said Rajiv De Silva, president and chief executive officer of Endo. "Endo will continue with a sharp strategic focus, lean operating model and improved execution of core businesses. Strategic acquisitions will also continue to play a key role in maximizing our growth potential and creating value for Endo International shareholders." | jimmyloser | |
29/3/2014 17:01 | apparently we are forecast to more than double fy to over £1.1million after "reassuring" interims. | jimmyloser | |
29/3/2014 16:30 | Afternoon all: If you pop down to W H Smiths this weekend and browse a copy of Shares Magazine then you will find in the latest issue 2 brief mentions of Circassia and one of Allergy Therapeutics. | algernon2 | |
29/3/2014 09:38 | well, well, well.! Our Canadian partner swallowed up by a whale of a business> Endo. | jimmyloser | |
28/3/2014 16:56 | 2533 - agree, just keep this board to AGY please | jimmyloser |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions